You are here

Novartis

It's Lights Out For Novartis And Verily's Glucose Monitoring 'Smart Lens' Project

It's Lights Out For Novartis And Verily's Glucose Monitoring 'Smart Lens' Project

Forbes

blood glucose monitoring

Flag link:

Novartis Calls for FDA Enforcement Against Biosimilar Misinformation

Novartis Calls for FDA Enforcement Against Biosimilar Misinformation

RAPS.org

citizen petitions

Flag link:

Novartis 'completely committed' to Sandoz, has no split-off plan

Novartis 'completely committed' to Sandoz, has no split-off plan

Yahoo/Reuters

Flag link:

Novartis files for Alcon spinoff, citing aging population and developing countries as top growth prospects

Novartis files for Alcon spinoff, citing aging population and developing countries as top growth prospects

Fierce Pharma

Flag link:

Ionis, Akcea succeed in heart drug trial, setting up Novartis decision

Ionis, Akcea succeed in heart drug trial, setting up Novartis decision

Biopharma Dive

Akcea Therapeutics

Ionis Pharmaceuticals

clinical trials

AKCEA-APO(a)-Lrx

Flag link:

Novartis builds its blockbuster case for Entresto, beating out a cheap ACE inhibitor in a head-to-head study

Novartis builds its blockbuster case for Entresto, beating out a cheap ACE inhibitor in a head-to-head study

Endpoints

Flag link:

As Novartis' other cancer launches struggle, Lutathera gets off to flying start

As Novartis' other cancer launches struggle, Lutathera gets off to flying start

Fierce Pharma

neuroendocrine tumors

Flag link:

Novartis Plans for 60 Regulatory Filings Over the Next Three Years

Novartis Plans for 60 Regulatory Filings Over the Next Three Years

BioSpace

drug development

Flag link:

Sticker shock: Novartis says its top drug prospect is worth $4M-$5M for a once-and-done use

Sticker shock: Novartis says its top drug prospect is worth $4M-$5M for a once-and-done use

Endpoints

spinal muscular atrophy

Flag link:

Novartis' Sandoz calls it quits on Rituxan biosimilar after FDA requests more data

Novartis' Sandoz calls it quits on Rituxan biosimilar after FDA requests more data

Fierce Pharma

Flag link:

Novartis abandons effort for U.S. approval of biosimilar rituximab

Novartis abandons effort for U.S. approval of biosimilar rituximab

Yahoo/Reuters

Flag link:

NASH Treatment: Will a Combo Drug Developed by Novartis and Pfizer Make the Cut?

NASH Treatment: Will a Combo Drug Developed by Novartis and Pfizer Make the Cut?

Xtalks

Flag link:

Novartis wins US nod for Humira biosimilar, but focus now on Europe

Novartis wins US nod for Humira biosimilar, but focus now on Europe

Biopharma Dive

Flag link:

Novartis May Beat Ironwood Pharmaceuticals to the Punch

Novartis May Beat Ironwood Pharmaceuticals to the Punch

Motley Fool

sickle cell disease

Ironwood Pharmaceuticals

Flag link:

Novartis Cuts 20% of Drug-Research Projects After Review

Novartis Cuts 20% of Drug-Research Projects After Review

Bloomberg

drug development

Flag link:

Big Pharma rivals Pfizer and Novartis team up on NASH combo targets

Big Pharma rivals Pfizer and Novartis team up on NASH combo targets

Fierce Biotech

drug development

Flag link:

Roche expands its PhIII program for Eylea rival as long-acting data back its blockbuster contender faricimab

Roche expands its PhIII program for Eylea rival as long-acting data back its blockbuster contender faricimab

Endpoints

Flag link:

This Big Pharma Bet Isn't Paying Off Yet

This Big Pharma Bet Isn't Paying Off Yet

Motley Fool

Flag link:

Endocyte deal showcases Novartis' complex manufacturing juggling act

Endocyte deal showcases Novartis' complex manufacturing juggling act

Biopharma Dive

drug manufacturing

Flag link:

FDA Grants Priority Review for Ruxolitinib (Jakafi) for Acute Graft-Versus-Host Disease

FDA Grants Priority Review for Ruxolitinib (Jakafi) for Acute Graft-Versus-Host Disease

CP Wire

graft vs host disease

Flag link:

Pages